

RUNX3 site-specific hypermethylation predicts PTC recurrence

Supplementary Table 1. Clinicopathological characteristics of PTC patients

Characteristics	No. of patients (%)
Gender	
Male	30 (25.00%)
Female	90 (75.00%)
Age (years)	
≤ 40	62 (51.67%)
> 40	58 (48.33%)
Lymph node metastasis	
Yes	60 (50.00%)
No	60 (50.00%)
TNM Stage	
< III	87 (72.50%)
≥ III	33 (27.50%)
Recurrence	
Yes	20 (16.67%)
No	100 (83.33%)

RUNX3 site-specific hypermethylation predicts PTC recurrence

Supplementary Table 2. Primer sequences used in this study

Genes	Forward primers (5'→3')	Reverse primers (5'→3')	Sequencing primers (5'→3')	Product length (bp)	No. of CpG sites	Annealing temperature (°C)
<i>CDH1</i>	ATTGTGAGTTTGAGGAAGTTAGTTTAGA	Biotin-ACTCCAAAAACCATAACTAACC	TTTGAGGAAGTTAGTTTAGATTTTA	117	8	57
<i>DAPK</i>	TGGATATGGGATTTTGTGTAGA	Biotin-ACCAAATAATCTCCATCTTTAAC	TTTTAAAAAGTAAATAGGTGA	201	5	58
<i>RARB</i>	ATTTTTGTAAAGGGGGGATTAG	Biotin-TTCCCAAAAAATCCCAAATTCTCCTT	GTTGTTTGAGGATTGG	181	10	59
<i>RUNX3</i>	Biotin-AAGGGGTGATTGTAGTGAAGTTTA	CTCTACCAATCCAACCCCACTTCTTCT	CCCACTTCTTCTTAAACC	169	8	60